Moore KN, et al. - In adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received three or more previous chemotherapy regimens, researchers assessed the activity of niraparib monotherapy as the fourth or later line of therapy. The treatment regimen used to treat the participants was oral niraparib 300 mg once daily continuously, beginning on day 1 and every cycle (28 days) thereafter until disease progression. Among women with heavily pretreated ovarian cancer, particularly in those with homologous recombination deficiency (HRD)-positive platinum-sensitive disease (including patients with a BRCA mutation and those with BRCA wild-type disease), niraparib had clinically germane activity. No new safety signals were found. Considering these findings, patients with HRD-positive ovarian cancer should be included in the treatment indication for poly(ADP-ribose) polymerase inhibitors.